US 11,655,463 B2
Endoinulinases
Itamar Yadid, Kibbutz Ayelet HaShachar (IL); Rami Cohen, Kibbutz Kfar-Blum (IL); and Livnat Afriat-Jurnou, Kibbutz Kfar-Szold (IL)
Assigned to MIGAL GALILEE RESEARCH INSTITUTE LTD., Kiryat Shmona (IL)
Filed by MIGAL GALILEE RESEARCH INSTITUTE LTD., Kiryat Shmona (IL)
Filed on Jan. 31, 2021, as Appl. No. 17/163,521.
Application 17/163,521 is a continuation of application No. 16/637,085, granted, now 10,941,386, previously published as PCT/IL2018/050872, filed on Aug. 7, 2018.
Claims priority of provisional application 62/541,820, filed on Aug. 7, 2017.
Prior Publication US 2021/0155914 A1, May 27, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 9/24 (2006.01); C12N 15/74 (2006.01)
CPC C12N 9/2402 (2013.01) [C12N 15/74 (2013.01); C12Y 302/01007 (2013.01)] 20 Claims
 
1. A modified endoinulinase being a modified wild-type T. purpuregenus endoinulinase comprising an amino acid sequence set forth in SEQ ID NO: 1 with a substitution being any one of: (i) glutamate at position 344 (E344) to K, H, or R; (ii) threonine at position 504 (T504) to M, S, or Y; and (iii) both (i) and (ii), or a functional fragment thereof comprising an amino acid sequence having at least 90% identity to a T. purpuregenus wild-type sequence of endoinulinase set forth in SEQ ID NO: 3, wherein any one of said modified endoinulinase comprising said substitution being any one of said (i) or (ii), and said functional fragment thereof further comprises one or more amino acid substitutions in positions corresponding to position 128, 316, or 350 of said wild-type T. purpuregenus endoinulinase as set forth in SEQ ID NO: 1, and wherein said modified endoinulinase is characterized by improved functional activity or solubility compared to said wild-type T. purpuregenus endoinulinase comprising said amino acid sequence set forth in SEQ ID NO: 1.